Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Net Cash Flow: 2022-2025

Historic Net Cash Flow for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to -$18.2 million.

  • Stoke Therapeutics' Net Cash Flow rose 58.23% to -$18.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.5 million, marking a year-over-year decrease of 66.34%. This contributed to the annual value of -$63.2 million for FY2024, which is 181.19% down from last year.
  • According to the latest figures from Q3 2025, Stoke Therapeutics' Net Cash Flow is -$18.2 million, which was up 89.53% from -$173.3 million recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Net Cash Flow ranged from a high of $146.8 million in Q1 2025 and a low of -$173.3 million during Q2 2025.
  • In the last 3 years, Stoke Therapeutics' Net Cash Flow had a median value of -$2.1 million in 2023 and averaged -$2.7 million.
  • As far as peak fluctuations go, Stoke Therapeutics' Net Cash Flow plummeted by 1,986.41% in 2024, and later surged by 1,241.69% in 2025.
  • Quarterly analysis of 4 years shows Stoke Therapeutics' Net Cash Flow stood at $160,000 in 2022, then surged by 815.62% to $1.5 million in 2023, then slumped by 1,588.46% to -$21.8 million in 2024, then skyrocketed by 58.23% to -$18.2 million in 2025.
  • Its Net Cash Flow stands at -$18.2 million for Q3 2025, versus -$173.3 million for Q2 2025 and $146.8 million for Q1 2025.